Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus

Authors:

Abstract
• A new strain of Lassa virus (LASV) was successfully isolated and characterized. • The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. • The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever.
Funding Information
  • National Key Research and Development Program of China (2023YFC2605504, 2022YFC2303300)
  • Chinese Academy of Sciences
  • National Natural Science Foundation of China (82172273, 31670165)
  • State Key Laboratory of Virology (2023JZZD-01)

This publication has 16 references indexed in Scilit: